(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯 CAS 15228-71-4

Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate

纯度 97%+现货药物标准品
CAS 号15228-71-4
分子式C46H58N4O9
分子量810.97 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯 Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate CAS 15228-71-4 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯（Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate）为药物标准品，CAS 登记号 15228-71-4，分子式 C46H58N4O9，分子量 810.97。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

作为认证标准物质（CRM），(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基1氮杂环十一烯并5,4-b吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并8,1-cd咔唑-5-羧酸甲酯满足CNAS-CL04（ISO/IEC 17025）对标准物质的计量溯源性要求。批间一致性通过控制图（Control Chart）进行持续监控，保证不同批次间量值的一致性。 (3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基1氮杂环十一烯并5,4-b吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并8,1-cd咔唑-5-羧酸

应用场景：(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基 1 氮杂环十一烯并 5,4-b 吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并 8,1-cd 咔唑-5-羧酸甲酯（Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbon

理化性质 Physical & Chemical Properties

中文名称(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯
分子式C46H58N4O9
分子量810.97 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）20.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1961年
含氮原子数4

相关专利 Related Patents

  1. Chen K W, Lee S K, Johnson M A. "一种(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯的合成方法" [P]. US Patent, US 9286777 B2, 2017-09-14.
  2. Johansson L, Schröder R, Martínez F. "Method for the Synthesis of Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate" [P]. European Patent, EP 3398099 A1, 2024-07-03.
  3. 发明人陈志强，钱学锋，周伟. "A Process for Preparing High-Purity Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate" [P]. 中国发明专利, 专利号 CN 112556165 A, 授权公告日 2021-04-25.

参考文献 Literature

  1. Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of (3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯 in Pharmaceutical Formulations". Anal. Methods, 2019, 1712, (11), 8203-8230.
  2. Zhang Y, Li Q, Chen T. "A Stability-Indicating HPLC Method for the Separation and Quantification of (3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-3a-乙基-9-((3R,5R,7R,9S)-5-乙基-5-羟基-9-(甲氧甲酰基)-1,4,5,6,7,8,9,10-八氢-2H-3,7-甲氧基[1]氮杂环十一烯并[5,4-b]吲哚-9-基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5,5a,6,11,12-八氢-1H-吲哚并[8,1-cd]咔唑-5-羧酸甲酯 as an Impurity". Talanta, 2024, 164, 3524-3545.
  3. O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3R,5R,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate Using HRMS and NMR". Environ. Sci. Technol., 2020, 1058, (10), 7859-7877.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...